In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
Binding of growth factors and cytokines to their cognate receptors on cell membranes triggers their endocytosis and degradation in lysosomes, thus providing a physiologically important negative feedback mechanism for cell signalling.
The ESCRT-II complex recognizes ubiquitinated receptors in the endosomal membrane, thus initiating their sorting to degradative lysosomes. (click to enlarge image)It is not known in detail how endocytosed receptors are trafficked to the degradative lysosomes, but work in Harald StenmarkÂ’s lab has uncovered several factors involved in this process. Among these are the so-called endosomal sorting complexes required for transport (ESCRTs), and Thomas Slagsvold in StenmarkÂ’s group has previously shown that the so-called GLUE domain in the ESCRT-II complex binds ubiquitin .
In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
From major journals, first or last author from the Institute for Cancer Research
Alampi MM, KozlÃková M, Mariangeli M, Civita S, Delcanale P, Mussini A, Diaspro A, Bianchini P, Weyergang A, Skarpen E, Berg K, Viappiani C, Abbruzzetti S, Selbo PK(2025) Light-enhanced cytotoxicity and intracellular trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab Biomed Pharmacother, 191, 118550(in press) DOI 10.1016/j.biopha.2025.118550, PubMed 40946581
Eggebø MS, Heinzelbecker J, Palashati H, Chandler N, Tran TT, Li Y, Yang W, Laos M, Blaas I, Rustad EH, Bollineni RC, Delic-Sarac M, Lund-Johansen F, Nielsen MM, Olweus J(2025) TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors Nat Immunol(in press) DOI 10.1038/s41590-025-02252-1, PubMed 40866620
Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA(2025) Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy Mol Oncol(in press) DOI 10.1002/1878-0261.70117, PubMed 40852937
Nie X, Sun Y, van Dijk DPJ, Deng M, Brecheisen R, Wang Z, Xia Q, Olde Damink SMW, Rensen SS(2025) Loss of Skeletal Muscle Mass Is Associated With Reduced Cytotoxic T Cell Abundance and Poor Survival in Advanced Lung Cancer J Cachexia Sarcopenia Muscle, 16(5), e70063 DOI 10.1002/jcsm.70063, PubMed 40931431
Alampi MM, KozlÃková M, Mariangeli M, Civita S, Delcanale P, Mussini A, Diaspro A, Bianchini P, Weyergang A, Skarpen E, Berg K, Viappiani C, Abbruzzetti S, Selbo PK(2025) Light-enhanced cytotoxicity and intracellular trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab Biomed Pharmacother, 191, 118550(in press) DOI 10.1016/j.biopha.2025.118550, PubMed 40946581
Ølnes ÅS, Teigen M, Laerdahl JK, Leren TP, Strøm TB, Bjune K(2025) Correction: Variants in the CETP gene affect levels of HDL cholesterol by reducing the amount, and not the specific lipid transfer activity, of secreted CETP PLoS One, 20(9), e0332400 DOI 10.1371/journal.pone.0332400, PubMed 40938802
